Stage II vaginal cancer responding to chemotherapy with irinotecan and cisplatin: a case report.
We report a patient with stage II primary vaginal cancer whose tumor disappeared on magnetic resonance imaging after a single course of neoajuvant chemotherapy using irinotecan and cisplatin. The regimen was 60 mg/m2 of cisplatin (day 1) and 60 mg/m2 of irinotecan (days 1, 8, 15). After addition of 1 course of cisplatin alone, radical surgery was performed. Histological examination of the excised tissue revealed no cancer cells. This is the first report on the good efficacy of chemotherapy with irinotecan and cisplatin for advanced vaginal cancer.
Umesaki
N
N
Department of Obstetrics and Gynecology, Osaka City University Medical School, Osaka 545-8585, Japan.
Kawamura
N
N
Tsujimura
A
A
Ichimura
T
T
Tanaka
T
T
Ogita
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D000077146:Irinotecan; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D012074:Remission Induction; D014625:Vaginal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin